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Abstract: Deep insight on cell cycle, checkpoints and cáncer. 
 
Introduction 
Maintenance of genomic integrity is a pre-requisite for 
a safe and long lasting life and prevents development of 
diseases associated with genomic instability such as 
cancer. DNA is constantly subjected and damaged by a 
large variety of chemical and physical agents, thus cells 
had to set up a number of surveillance mechanisms that 
constantly monitor the DNA integrity and the cell cycle 
progression and in the presence of any type of DNA 
damage activate pathways that lead to cell cycle 
checkpoints, DNA repair, apoptosis and transcription. 
In recent years checkpoint pathways have been 
elucidated as an integral part of the DNA damage 
response and in fact dysfunctions or mutations of these 
pathways are important in the pathogenesis of 
malignant tumors. Understanding the molecular 
mechanisms regulating the cell cycle progression and 
checkpoints and how these processes are altered in 
malignant cells may be crucial to better define the 
events behind such a complex and devastating desease 
like cancer (Poehlmann and Roessner, 2010; 
Vermeulen et al., 2003; Aarts et al., 2013; Kastan and 
Bartek, 2004). 
Cell cycle regulation 
The cell cycle is a succession of very well organized 
molecular events that give the ability to the cell to 
produce the exact itself's copy. The DNA replication 
and the segregation of replicated chromosomes are the 
main events of the cell cycle. The DNA replication 
occurs during the so called S phase (synthetic phase) 
which is preceded by the DNA synthesis preparatory 
phase (Gap1 or G1 phase), whereas the nuclear division 
occurs in mitosis (M phase) and is preceded by the 
mitotic preparatory phase (gap 2 or G2 phase). The G1,  
S and G2 phases represent the interphase of a 
proliferating cell and constitute the time lapse between 
two consecutive mitoses. The differentiated cells that 
do not proliferate enter in the so called G0 phase which 
is a steady state phase or resting phase (Vermeulen et 
al., 2003). 
The progression of a cell through the cell cycle is 
strictly regulated by key regulatory proteins called 
CDK (cyclin dependent kinase) which avoid the 
initiation of a cell cycle phase before the completion of 
the preceding one. The cdks are a family of 
serine/threonine protein kinases that are activated at 
specific points of the cell cycle consisting of a catalytic 
subunit with a low intrinsic enzymatic activity and of a 
fundamental positive regulatory subunit called cyclin 
(Pavletich, 1999). Cyclin protein levels rise and fall 
during the cell cycle, activating the corresponding cdk, 
whereas the cdk protein levels are kept constant 
throughout the cell cycle. Once the complex cdk-cyclin 
is formed, it gets activated by the protein CAK (cdk 
activating protein) which phosphorylates the complex 
ensuring the subsequent phosphorylation of target gene 
products required for the progression of the cell 
through the cell cycle (Morgan, 1995). When quiescent 
cells are stimulated by mitogen signals, CDK4 and 
CDK6 are activated by association with D type cyclins. 
These above cited cdk-cyclin complexes are important 
for the progression through the G1 phase and the 
restriction point preparing the cell to the replicative 
phase by phosphorylating the oncosuppressor protein 
pRb which causes the activation of the E2F family 
transcription factors. The activation of CDK4 and 
CDK6 is followed by the subsequent activation of 
CDK2 by cyclin E and cyclin A, which in turn initiates 
DNA replication. As the DNA replication process  
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finishes, the Cdk1/cyclin B complex is activated 
leading to mitosis (Vermeulen et al., 2003; Sherr and 
Roberts, 1999). Until the end of G2 phase, CDK1 is 
phos-phorylated at Thr14 and Tyr15 by the kinases 
WEE1 and MYT1, resulting in inhibition of cyclin B-
CDK1 activity. Mitotic entry is ultimately initiated by  
depho-sphorylation of these residues by the CDC25 
family of phosphatases, initiating a positive feedback 
loop that stimulates cyclin B-CDK1 activity and entry 
into mitosis (Lindqvist et al., 2009). The activation 
status of the cdk-cyclin complexes is also monitored by 
negative regulation of the ATP binding site by 
phosphorylation in specific residues and subsequent 
reactivation by specific phosphatases which 
dephosphorylate the same residues. Inhibitory proteins 
also contribute to negatively regulate the cdks by 
forming either binary complexes with cdks or ternary 
complexes with cyclin cdk dimers (figure 1). Three 
distinct families of these so called cyclin dependent 
kinase inhibitors (CKI) can be distinguished. The first 
one is called INK family and is composed by four 
members: p15, p16, p18 and p19. They mainly regulate 
the G1-S transition of the cell cycle targeting to CDK4 
and CDK6 by binding the cdk subunit and causing a 
conformational change of the kinases which become 
inactive precluding the cyclin binding. The second 
family of inhibitors is the Cip/Kip family and consists 
of three members: p21cip1, p27kip1 and p57kip2. The 
components of this group negatively regulate the 
cdk2/cyclinA and cdk2/cyclinE complexes whereas 
they positively regulate the cdk4/6 cyclinD complexes 
by facilitating and stabilizing the association of cyclin 
and CDKs. The final class of inhibitors is the pRb 
protein family which consists of two members: p107 
and p130. These proteins, better known as 
transcriptional inhibitors, act as potent cyclin E/A-cdk2 
inhibitors by binding both to cyclin and to cdk sites 
(Vermeulen et al., 2003; Cobrinik, 2005). 
An additional level of cdk regulation is the control of 
nuclear import/export which can be easily exemplified 
by the cyclinB1-Cdk1 complex that is kept out of the 
nucleus through an active nuclear export until late G2, 
when the nuclear exporting signals are inactivated by 
phosphorylation ensuring nuclear accumulation. The 
regulation of the Cdk1-cyclinB1 complex via 
cytoplasmic sequestration together with the negative 
regulatory phosphorylation of Cdk1 prevents premature 
phosphorylation of mitotic targets and the entry in 
mitosis (Yang et al., 1998). Other examples are the 
CDK inactivating kinases Wee1 and Myt1 located 
respectively in the nucleus and Golgi complex 
protecting the cells from premature mitosis and the 14-
3-3 group of proteins that regulate the intracellular 
trafficking of different proteins such as the phosphatase 
Cdc25C (Peng et al., 1997). The above mentioned 
events are very well monitored by signaling pathways 
called checkpoints which constantly make sure that 
upstream events are successfully completed before the 
initiation of the next phase. It's in fact important that 
alterations in duplication of the DNA during S phase do 
not occur, to avoid the segregation of aberrant genetic 
material to the daughter cells hence ensuring accurate 
genetic information's transmission throughout cellular 
generations. Lack of fidelity in cell cycle processes 
creates a situation of genetic instability which 
contributes to the development of cancer desease. In 
cancer, the genetic control of cell division is altered 
resulting in a massive cell proliferation. Mutations 
mainly occur in two classes of genes: proto-oncogenes 
and tumor suppressor genes.  
In normal cells the proto oncogenes products act at 
different levels in pathways that stimulate proper cell 
proliferation while the mutated proto-oncogenes or 
oncogenes can promote tumor growth due to 
uncontrolled cell proliferation. Tumor-suppressor genes 
normally keep cell numbers down, either by halting the 
cell cycle and thereby preventing cellular division or by 
promoting programmed cell death. When these genes 
are rendered non-functional through mutation, the cell 
becomes malignant. Defective proto-oncogenes and 
tumor-suppressor genes act similarly at a physiologic 
level: they promote the inception of cancer by 
increasing tumor cell number through the stimulation 
of cell division or the inhibition of cell death or cell 
cycle arrest. Uncontrolled cell proliferation which 
evolves in cancer can occur through mutation of 
proteins important at different levels of the cell cycle 
such as CDK, cyclins, CKI and CDK substrates. 
Defects in cell cycle checkpoints can also result in gene 
mutations, chromosome damages and aneuploidy all of 
which can contribute to tumorigenesis. 
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Figure 1. Schematic summary of the levels of regulation of the cyclin dependent kinases (Cdk). 1 and 2. Synthesis and 
degradation of cyclins at specific stages of the cell cycle. 3. Association of cdks to cyclins in order to be active. 4. Activation of the 
cdk/cyclin complexes by CAK. 5. Inactivation of cdk/cyclin complexes by phosphorylation at thr14 and tyr15 (5a) and reactivation by 
phosphatases acting on these sites (5b). 6. Cdk inhibitor proteins (CKI) preventing either the assembly of cdk/cyclin complexes (6a) or 
the activation of the cdk in the complex (6b). The activated cdk/cyclin complexes can phosphorylate substrates necessary for transition to 
the next cell cycle phase. 
 
Targeting cell cycle regulators in 
cancer 
Cyclins and their associated cyclin-dependent kinases 
(CDKs) are the key drivers of the cell cycle and 
specific transitions in the cell cycle are controlled 
solely by specific CDKs. When this specificity is 
maintained in tumour cells, selective inhibition of these 
kinases presents a potential attractive strategy to 
tumour therapy, suggesting that a therapeutic window 
could be achieved. In normal cells, commitment for the 
progression through the cell cycle and beginning of 
replication process is controlled by cyclin D-CDK4/6 at 
the restriction point (Musgrove et al., 2011). CDK4 and 
CDK6 initiate the phosphorylation of the 
retinoblastoma (RB) protein family, resulting in 
dissociation and thereby activation of E2F transcription 
factors which initiate the S phase gene expression 
program, including the expression of both cyclin E and 
CDK2, resulting in further RB phosphorylation and 
ultimately S phase entry (Malumbres and Barbacid, 
2009). Deregulation of the restriction point is a 
common event in cancer, yet CDK4/6 is a potential 
therapeutic target in only a subset of cancers. Many 
oncogenes overcome the restriction point by promoting 
CDK4/6 activity (Huillard et al., 2012). CDK4 can be 
activated more directly by point mutation/amplification 
or via amplification of CCND1 (cyclin D1) (Curtis et 
al., 2012; Kim and Diehl, 2009), or indirectly via  
mutation, silencing by methylation or homozygous 
deletion of CDKN2A (encoding p14ARF and 
p16INK4A) (Pinyol et al., 1997). Elevated levels of 
phosphorylated RB and relatively low levels of 
p16INK4A may provide biomarkers of CDK4/6 
dependence (Konecny et al., 2011). Mouse double 
knockout studies of CDK4 and CDK6 suggest that the 
CDK4/6 kinases are only essential in specific tissue 
compartments (Malumbres et al., 2004), presenting a 
therapeutic window where tumour cells are more 
reliant on CDK4/6 than many proliferating normal 
tissues. CDK4/6 inhibition has great promise for the 
treatment of multiple cancer types, and multiple clinical 
studies are ongoing. 
Cyclin B-CDK1 activity, as mentioned before, governs 
mitotic entry and is tightly controlled by an intricate 
network of feedback loops (Lindqvist et al., 2009). A 
number of potential issues make CDK1 a less attractive 
target than CDK4/6. CDK1 is essential for mitosis in 
most normal cells, which may limit the ability to dose 
CDK1 inhibitors in the clinic. If CDK1 inhibition 
causes a reversible G2 arrest in cancer cells, it is 
unclear whether a CDK1 inhibitor could be dosed 
sufficiently to achieve tumour control and studies are 
undergoing. Polo-like kinase 1 (PLK1) and Aurora 
kinase A (AURKA), promote progression through 
mitosis. Inhibition of these kinases presents a potential 
therapeutic opportunity through inhibiting appropriate 
progression through mitosis. PLK1 is a serine/threonine  
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kinase involved in centrosome maturation, spindle 
formation, chromosome segregation and cytokinesis 
(Strebhardt, 2010). Besides its mitotic functions, PLK1 
is essential for inactivating or removing key 
components of the DNA damage response, such as 
CHK1 (via Claspin), WEE1 and 53BP1, to inactivate 
checkpoint signalling and promote cell cycle 
resumption (Strebhardt, 2010). Inhibition of PLK1 
causes cells to arrest in mitosis with a monopolar or 
disorganised spindle followed by mitotic cell death 
(Lens et al., 2010). The Aurora kinase family members 
(A, B and C) each coordinate distinct processes during 
cell division. AURKA is critical for centrosome 
maturation and proper formation of the mitotic spindle. 
Selective inhibition of AURKA leads to abnormal 
mitotic spindles and a temporary mitotic arrest 
followed by chromosome segregation errors as cells 
exit mitosis. The amplification and overexpression of 
AURKA has been reported in many human tumours, 
including breast, colon, neuroblastoma, pancreatic and 
ovarian cancers, with high AURKA expression levels 
being associated with poor prognosis and genomic 
instability (Lens et al., 2010). This makes AURKA an 
attractive anti-mitotic drug target and as in fact, 
AURKA inhibitors are currently being evaluated pre-
clinically and in clinical trials. Clinical data with 
mitotic kinase inhibitors have not yet been really 
promising. The AURKA-selective inhibitor MLN8237 
(alisertib) had low levels of activity in a phase II study 
in unselected ovarian cancer (Matulonis et al., 2012), 
and only modest activity was seen in initial clinical 
trials of PLK1 inhibitors (Olmos et al., 2011). 
However, none of these studies have yet selected for 
potentially sensitive tumours, so further insights in 
determining the most responsive tumors are required in 
future trials. 
DNA damage checkpoint 
A faithful transmission of genetic informations from 
one cell to its daughters requires the ability of a cell to 
survive to spontaneous and induced DNA damage to 
minimize the number of heritable mutations. To 
achieve this fidelity, cells have evolved surveillance 
mechanisms composed by an intricate network of 
checkpoint proteins that tells the cell to stop or delay 
the cell cycle progression providing enough time for 
DNA repair. When the damage could not be repaired 
cells undergo apoptosis. Many different lesions can 
occur in the cells which are coupled to different repair 
mechanisms. First, normal metabolic processes or 
exposure to external ionizing radiations generate free 
oxygen radicals and can break the phospho diester 
bonds in the backbone of the DNA helix (single strand 
break). When two of these breaks are close to each 
other but on opposite DNA strands, a double strand 
break (DSB) is present. Second, alkylating agents can 
modify purine bases and can cause intra strand or inter  
strand crosslinks. Inhibitors of DNA topoisomerase can 
cause DNA lesions leading to enhanced single or 
double strand  
break depending on which topisomerase is inhibited 
and on the phase of the cell cycle. Different 
mechanisms are required to repair the damage to the 
DNA backbone or to the DNA bases and the repairing 
mechanisms may also vary depending on the different 
phases of the cell cycle.  
The DNA damage checkpoint activation pathway is the 
response to a variety of internal factors (e.g. incomplete 
DNA replication due to stalled replication forks, 
reactive oxygen species-ROS) and external sources 
(e.g. UV light, ionizing radiation-IR, DNA-damaging 
chemotherapeutic agents).  
The checkpoint activation is part of the signaling 
network (the DNA damage response) that involves 
multiple pathways including checkpoints, DNA repair, 
transcriptional regulation and apoptosis (Bartek and 
Lukas, 2007; Branzei and Foiani, 2008).  
When DNA damage occurs, a signal transduction 
pathway cascade is activated in which sensor proteins 
recognize the damage and transmit signals that are 
amplified and propagated by adaptors/mediators to the 
downstream effectors that connect the checkpoint with 
the cell cycle machinery and final cell fate.  
Generally the cell cycle progression is hampered at the 
stage in the cell cycle where the cell was at the time of 
injury: before entry in S phase (G1/S phase 
checkpoint), during S phase progression (intra S phase 
or S phase checkpoint), before mitotic entry (G2/M 
phase checkpoint) or during mitosis (mitotic spindle 
checkpoint).  
The cell cycle arrest gives cell time to fix the damage 
by activating a series of DNA repair pathways. If the 
damage exceeds the capacity for repair, pathways 
leading to cell death are activated mostly by apoptosis 
(by p-53 dependent and independent pathways) (Zhou 
and Elledge, 2000). 
Chk1 protein kinase is one of the main component of 
DNA damage checkpoints pathways and represent a 
vital link between the upstream sensors of the 
checkpoints (i.e. ATM and ATR) and the cell cycle 
engine (i.e. cdk/cyclins) (Zhou and Elledge, 2000; 
Stracker et al., 2009).  
A brief description of its network is herein summarized 
to show just an example of how in general checkpoints 
proteins are strictly interconnected and inter-related 
each others.  
Chk1 regulates the checkpoints by targeting the Cdc25 
family of dual specificity phosphatases, Cdc25A at the 
G1/S and S phase checkpoints and Cdc25A and 
Cdc25C at the G2/M checkpoint.(Peng et al., 1997; 
Mailand et al., 2000)  
Phosphorylation of Cdc25A by Chk1 at multiple sites 
increases proteosomal degradation of the phosphatase 
and inability of Cdc25A to interact with its cyclin/cdks 
substrates.  
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Chk1 phosphorylates Cdc25C at ser216, leading to 
formation af a complex with 14-3-3 proteins and 
cytoplasmic sequestration of the phosphatase (Peng et 
al., 1997; Mailand et al., 2000; Zhao et al., 2002), thus 
avoiding activation of the cyclinB1-CDK1 complex 
which regulates the entry in mitosis. Chk1 is activated 
after DNA damage, which ultimately causes single 
strand (ss) DNA breaks, by ATM- and ATR-dependent 
phosphorylation of C-terminal residues (ser317 and 
ser345). In particular, after formation of ssDNA breaks 
(induced for example by UV, replication stresses, DNA 
damaging agents), replication protein A (RPA) binds to 
ssDNA and recruits Rad17/9-1-1 and ATR/ATRIP 
complexes, leading to Chk1 phosphorylation. Chk1 
activation by ATR also requires mediators such as 
claspin, BRCA1, TOBP1. Indirectly, as ssDNA breaks 
also serve as an intermediate of double strand DNA 
(dsDNA) breaks, ATM too is involved in Chk1 
activation. ATM is recruited at the level of DSBs 
(induced by IR for example) by the MRN complex 
leading to Chk2 activation. ATM and MRN mediate 
DSB resection leading to ssDNA formation as an 
intermediate structure of DNA repair, leading to Chk1 
activation through RPA/ATR-ATRIP recruitment 
(Bartek and Lukas, 2007; Gottifredi and Prives, 2005; 
Jazayeri et al., 2006). 
Chk1 also plays a role in the mitotic spindle checkpoint 
which ensures the fidelity of mitotic segregation during 
mitosis, preventing chromosomal instability and 
aneuploidy (Carrassa et al., 2009; Zachos et al., 2007; 
Suijkerbuijk and Kops, 2008; Chilà et al., 2013). 
Targeting cell cycle checkpoints as 
therapeutic strategy in cancer 
The DNA damage response requires the integration of 
cell cycle control via checkpoint signalling to allow 
time for repair to prevent DNA damage before DNA 
replication and mitosis take place. The importance of 
checkpoints pathways in the cellular response to DNA 
damage (both endogenous and exogenous) is at the 
basis of the use of checkpoint inhibitors to increase the 
efficacy of cancer radio- and chemo-therapy. Chemo- 
and radio-therapy are strong inducers of the DNA 
damage response pathways being able to cause 
different types of DNA damage and variably able to 
activate checkpoints, and the abrogation of these 
checkpoints can potentiate the cytotoxic activity of 
various anticancer agents (Poehlmann and Roessner, 
2010). Targeting the S and G2 checkpoints has been 
considering attractive for cancer therapy because loss 
of G1 checkpoint control is a common feature of cancer 
cells (due to mutation of tumor suppressor protein p53), 
making them more reliant on the S and G2 checkpoints 
to prevent DNA damage triggering cell death, while 
normal cells also depend on a functional G1 checkpoint 
(Dai and Grant, 2010; Ma et al., 2011). Experimental 
evidence showed that inhibiting the S and G2 
checkpoints by inactivation of ATR or CHK1 
abrogated DNA damage-induced G2 checkpoint arrest 
and sensitized cancer cells to a variety of DNA-
damaging chemotherapeutic agents (Carrassa et al., 
2004; Ganzinelli et al., 2008; Massagué, 2004). 
Furthermore, oncogenic replicative stress may render 
cancer cells sensitive to inhibitors that prevent the S 
and G2 checkpoints as single agents. As mentioned 
previously, CHK1 is a key signalling kinase involved 
in the intra-S phase and G2/M checkpoints (Kastan and 
Bartek, 2004). In response to replication stress or 
genotoxic insults, CHK1 is activated via ATR-
dependent phosphorylation. During unperturbed S 
phase, CHK1 controls replication fork speed and 
suppresses excess origin firing (Petermann et al., 2010), 
prevents premature activation of cyclin B-CDK1 and 
may be involved in spindle checkpoint signalling 
(Zachos et al., 2007; Chilà et al., 2013, Carrassa and 
Damia, 2011). Oncogene driven replication is abnormal 
and results in high levels of replication stress, and 
inhibition of CHK1 may increase the replication stress 
to sufficiently high levels to be lethal as a single agent 
in certain contexts (Jazayeri et al., 2006; Syljuåsen et 
al., 2005). The tyrosine kinase Wee1, together with 
Chk1, has also to be considered a crucial checkpoint 
protein controlling S and G2 checkpoint (Figure 2). 
The WEE1 kinase prevents mitotic entry via inhibitory 
phosphorylation of CDK1 at Tyr15 (Lindqvist et al., 
2009). Recently, it is becoming clear that WEE1 is also 
required for the maintenance of genome integrity 
during DNA replication (Sørensen and Syljuåsen, 
2012; Beck et al., 2012). WEE1 controls CDK1 and 
CDK2 activity during S phase, thereby suppressing 
excessive firing of replication origins, promoting 
homologous recombination, and preventing excessive 
resection of stalled replication forks (Beck et al., 2012; 
Krajewska et al., 2013). 
Thus both Chk1 and Wee1 are required during normal 
S phase to avoid deleterious DNA breakage, and 
thereby prevent loss of genome integrity in the absence 
of exogenous DNA damage (Sørensen and Syljuåsen, 
2012). Several Chk1 and Wee1 inhibitors have now 
been developed and tested in combination with DNA 
damaging agents to increase their efficacy, especially in 
tumors with a defective G1/S checkpoint (e.g. p53 
defects) (Carrassa and Damia, 2011; Stathis and Oza, 
2010) 
WEE1 inhibitors have been developed, and some have 
entered into clinical trials but clinical data are still 
limited. 
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Figure 2. Schematic representation of the role of Chk1 and Wee1 in regulation of the CDK-cyclin complexes involved in S phase and M 
phase entry. 
 
The pyeazolo-pyrimidine derivative MK-1775 is the 
most potent and highly selective inhibitor of Wee1, and 
has recently reached phase I (in combination with 
gemcitabine, cisplatin, or carboplatin) and II studies (in 
combination with paclitaxel and carboplatin in ovarian 
cancer) (Stathis and Oza, 2010; De Witt Hamer et al., 
2011). Most research has focused on the development 
of CHK1 inhibitors, which have entered clinical 
studies. UCN 01 was the first of this type of inhibitor to 
enter clinical trials, but after Phase II trials it was 
discontinued owing to dose-limiting toxicities and a 
lack of convincing efficacy that was probably due to 
poor specificity and pharmacokinetics. The newer, 
more specific inhibitors of CHK1 have generally been 
combined with gemcitabine in Phase I studies, in which 
myelosuppression was the major toxicity that led to the 
termination of the trials, and no efficacy data have yet 
been presented (Carrassa and Damia, 2011; Blasina et 
al., 2008). Recently, a selective orally available 
inhibitor developed from a high-throughput screening 
hit, GNE-900, gave promising pre-clinical studies and 
is now undergoing Phase I clinical trials (Blackwood et 
al., 2013). 
Synthetic lethality approach in 
cancer therapy 
The most promising prospect for the future of cancer 
treatment seems to be the exploitation of dysregulated 
DNA Damage Response, by the synthetic lethality 
approach. The synthetic lethality concept states that 
mutations of two different genes are not lethal in the 
cells when they occur at once, but are synthetically 
lethal, causing cells to die, if they occur 
simultaneously. Synthetic lethal interactions have been 
widely reported for loss and gain of function mutations. 
The synthetic lethality-driven approach offers the ideal 
cancer therapy as it allows indirect targeting of non-
druggable cancer-promoting lesions with 
pharmacological inhibition of the druggable synthetic 
lethal interactor and as it should be exclusively 
selective for cancer cells, and well tolerated by healthy 
normal cells, that lack the cancer-specific mutation, 
with a wide therapeutic window (Kaelin Jr, 2005; 
Canaani, 2009). This concept is at the basis of the 
efficacy in preclinical systems of PARP inhibitors in 
homologous recombination defective cells, due to 
mutation of genes such as BRCA1/BRCA2 and it has 
already undergone proof-of-principle in the clinical 
setting. Substantial durable antitumor activity was 
observed after treatment with PARP inhibitors in 
patients with BRCA1/2-mutated cancers, including 
ovarian, breast and prostate cancers (Bryant et al., 
2005; Fong et al., 2009). Chk1 inhibition has been 
proposed as a strategy for targeting FA (Fanconi 
Anemia) pathway deficient tumors. In fact, tumor cells 
deficient in the FA pathway are hypersensitive to Chk1 
inhibition, suggesting a possible use of these inhibitors 
in FA deficient tumors (Chen et al., 2009). The FA 
pathway is a DNA repair pathway required for the 
cellular response to different DNA damaging agents, 
including cross-linking agents (e.g. cis-platinum) in 
cooperation with the homologous recombination 
pathway.  
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Figure 3. Schematic representation of the effects of Chk1 and Wee1 inhibition on CDK-CYCLIN complex regulation, that gets more 
activated being unphosphorylated. 
 
A range of sporadic tumors with genetic and epigenetic 
disruption of the FA genes have been reported. 
Hyperactive growth factor signalling and oncogene-
induced replicative stress increase DNA breakage that 
activates the ATR-CHK1 pathway, and some examples 
of the synthetic lethality of checkpoint or DNA repair 
inhibitors in cells harbouring activated oncogenes have 
been identified. ATR knockdown was synthetically 
lethal in cells transformed with mutant KRAS (Gilad et 
al., 2010), and inhibition of CHK1 and CHK2 
significantly delayed disease progression of 
transplanted MYC-overexpressing lymphoma cells in 
vivo (Ferrao et al., 2011). 
Many recent studies with a high throughput siRNA 
screening approach led to identification of other 
possible target genes synthetically lethal with Chk1 
inhibitors. Recently two distinct siRNA high-
throughput screening identified Wee1 as in synthetic 
lethality with Chk1 (Davies et al., 2011; Carrassa et al., 
2012) and combined treatment of Chk1 and Wee1 
inhibitors showed a strong synergistic cytotoxic effect 
in various human cancer cell lines (ovary, breast, 
prostate, colon). The strong in vitro synergistic effect of 
the combination translates to tumor growth inhibition 
in vivo (Carrassa et al., 2012; Russell et al., 2013). 
Simultaneous inhibition of CHK1 and WEE1 induces 
cell death through a general mis-coordination of the 
cell cycle (figure 3), which leads to DNA damage and 
collapsed replication forks during S phase (Carrassa et 
al., 2012; Guertin et al., 2012), and to premature 
mitosis directly from S phase. These data have been 
recently corroborated by other groups, suggesting that 
at least in solid tumors this drug combination could be 
a very new promising anticancer strategy deserving 
clinical investigation (Russell et al., 2013; Guertin et 
al., 2012). Many other successful synthetic lethality 
combinations exist and many more probably need to be 
explored and they will provide in the near future new 
potential effective tools for cancer therapy (Reinhardt 
et al., 2013; Curtin, 2012). 
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